Update on medication abortion.

  title={Update on medication abortion.},
  author={Margaret W Beal},
  journal={Journal of midwifery & women's health},
  volume={52 1},
This article provides an overview of medication abortion in the United States 6 years after the approval of mifepristone (RU486; Mifeprex; Danco Laboratories, LLC, New York, NY) by the US Food and Drug Administration (FDA). The adoption of mifepristone is considered in the context of epidemiologic data on abortion, abortion access, and the safety of abortion. The risks of medication and aspiration abortion are discussed in the context of abortion-related mortality, recent experience with… CONTINUE READING